Who is sponsoring NCT05006599?

NCT05006599 is sponsored by Wake Forest University Health Sciences.

What condition does NCT05006599 study?

NCT05006599 studies Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease, Early Onset.

What drugs are being tested in NCT05006599?

Interventions: Insulin (Humulin® R U-100), Placebo, Aptar Pharma CPS Intranasal Delivery Device.

What is the status of NCT05006599?

NCT05006599 is currently WITHDRAWN.

Last reviewed 2025-07-25 · How we verify

Study of Nasal Insulin to Fight Forgetfulness (SNIFF) - 3-Week Aptar CPS Device

NCT05006599 Phase 2 WITHDRAWN

The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body. It works by lowering levels of glucose (sugar) in the blood. This study is measuring how much insulin the device delivers. In addition, this study will look at the effects of insulin or placebo administered intra-nasally using an intranasal delivery device on memory, blood, and cerebrospinal fluid (CSF).

Details

Lead sponsor	Wake Forest University Health Sciences
Phase	Phase 2
Status	WITHDRAWN
Start date	2025-05
Completion	2031-05

Conditions

Mild Cognitive Impairment
Cognitive Impairment
Alzheimer Disease, Early Onset

Interventions

Insulin (Humulin® R U-100)
Placebo
Aptar Pharma CPS Intranasal Delivery Device

Primary outcomes

Percentage of Prescribed Dose Taken — Week 4
Participant self-reported medication adherence information will be calculated by study staff on a 0%-100% scale. A score below 80% indicates low medication adherence and a score of 80% or higher indicates high medication adherence.